A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Children 6 to <12 Years of Age With Uncontrolled Persistent Asthma

Trial Profile

A Randomized, Double-blind, Placebo-controlled, Parallel Group Study to Evaluate the Efficacy and Safety of Dupilumab in Children 6 to <12 Years of Age With Uncontrolled Persistent Asthma

Recruiting
Phase of Trial: Phase III

Latest Information Update: 09 Aug 2017

At a glance

  • Drugs Dupilumab (Primary) ; Prednisolone; Prednisolone; Prednisone
  • Indications Asthma
  • Focus Therapeutic Use
  • Acronyms VOYAGE
  • Sponsors Sanofi
  • Most Recent Events

    • 04 Jul 2017 Planned End Date changed from 23 Sep 2020 to 29 Oct 2020.
    • 04 Jul 2017 Planned primary completion date changed from 23 Sep 2020 to 29 Oct 2020.
    • 17 May 2017 Planned End Date changed from 1 Aug 2020 to 23 Sep 2020.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top